The key roles of TGF-β1 and PGE2 in sustaining an immunosuppressive milieu in the TME are highlighted by an, albeit small, phase I “single-center, open-label, dose-escalation study” undertaken in patients with cSCC in situ. Here, TGFB1 is linked to skin squamous cell carcinoma.